Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone33-1-53-77-44-00
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$39.60 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Sanofi (NYSE:SNY) Frequently Asked Questions
What is Sanofi's stock symbol?
Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."
How often does Sanofi pay dividends? What is the dividend yield for Sanofi?
Sanofi declared an annual dividend on Tuesday, February 26th. Shareholders of record on Wednesday, May 8th will be given a dividend of $1.7395 per share on Friday, May 31st. This represents a yield of 4.2%. The ex-dividend date is Tuesday, May 7th. View Sanofi's Dividend History.
How were Sanofi's earnings last quarter?
Sanofi SA (NYSE:SNY) posted its earnings results on Monday, July, 29th. The company reported $0.74 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.07. The firm earned $8.63 billion during the quarter, compared to the consensus estimate of $8.42 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The company's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.25 earnings per share. View Sanofi's Earnings History.
When is Sanofi's next earnings date?
What guidance has Sanofi issued on next quarter's earnings?
Sanofi updated its FY 2019 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $5.74-5.74 for the period.
What price target have analysts set for SNY?
9 analysts have issued 12-month price targets for Sanofi's shares. Their predictions range from $50.00 to $52.00. On average, they anticipate Sanofi's stock price to reach $51.00 in the next year. This suggests a possible upside of 9.8% from the stock's current price. View Analyst Price Targets for Sanofi.
What is the consensus analysts' recommendation for Sanofi?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi.
What are Wall Street analysts saying about Sanofi stock?
Here are some recent quotes from research analysts about Sanofi stock:
- 1. According to Zacks Investment Research, "Sanofi’s focus on streamlining operations and pursuing business development deals is encouraging. Sanofi’s Specialty Care segment, particularly, is on a strong footing with recent FDA approvals of new drugs Libtayo and Cablivi, and Dupixent for its second indication in asthma. Dupixent could prove to be an important growth driver. The performance of the Vaccines and Consumer Healthcare franchises has also improved of late. Sanofi’s R&D pipeline is strong and it has delivered important results with several positive data read-outs and the achievement of regulatory milestones this year. However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Shares have outperformed the industry in the past six months." (8/29/2019)
- 2. HC Wainwright analysts commented, "We used a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 7.3% discount rate and 22% effective tax rate. Our assumptions assign a 90% probability of launch to DARZALEX in smoldering MM." (2/28/2019)
Has Sanofi been receiving favorable news coverage?
Media stories about SNY stock have trended somewhat negative on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sanofi earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Sanofi.
Who are some of Sanofi's key competitors?
Some companies that are related to Sanofi include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Eli Lilly And Co (LLY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Sanofi own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Johnson & Johnson (JNJ), Gilead Sciences (GILD), AT&T (T), General Electric (GE), Bank of America (BAC), Merck & Co., Inc. (MRK), Exxon Mobil (XOM), Alibaba Group (BABA), Pfizer (PFE) and AbbVie (ABBV).
Who are Sanofi's key executives?
Sanofi's management team includes the folowing people:
- Mr. Olivier Brandicourt, CEO & Director (Age 62)
- Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)
- Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
- Mr. Bruno Ménard, Chief Information officer
- Mr. George Grofik, Head of Investor Relations
Who are Sanofi's major shareholders?
Sanofi's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.68%), Barrow Hanley Mewhinney & Strauss LLC (0.54%), Invesco Ltd. (0.30%), Bank of America Corp DE (0.16%), Morgan Stanley (0.13%) and Northern Trust Corp (0.09%). View Institutional Ownership Trends for Sanofi.
Which institutional investors are selling Sanofi stock?
SNY stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Bank of America Corp DE, Balyasny Asset Management LLC, Brandes Investment Partners LP, United Services Automobile Association, Bank of Montreal Can, BlackRock Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for Sanofi.
Which institutional investors are buying Sanofi stock?
SNY stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, Nuveen Asset Management LLC, Schafer Cullen Capital Management Inc, Fisher Asset Management LLC, Jane Street Group LLC, Royal Bank of Canada and Miller Howard Investments Inc. NY. View Insider Buying and Selling for Sanofi.
How do I buy shares of Sanofi?
Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sanofi's stock price today?
One share of SNY stock can currently be purchased for approximately $46.46.
How big of a company is Sanofi?
Sanofi has a market capitalization of $116.34 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. View Additional Information About Sanofi.
What is Sanofi's official website?
How can I contact Sanofi?
Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]
MarketBeat Community Rating for Sanofi (NYSE SNY)
| Community Ranking: | | 2.2 out of 5 ( ) |
| Outperform Votes: | | 428 (Thanks for Voting!) |
| Underperform Votes: | | 533 (Thanks for Voting!) |
| Total Votes: | | 961 |
